Figure 1From: Clinical and biochemical effects of a combination botanical product (ClearGuard™) for allergy: a pilot randomized double-blind placebo-controlled trial Nasal Symptom Scale scores by allergen challenge dose and treatment. Not all subjects underwent the full dose-response due to maximum possible response before reaching the full dose (6250 AU/ml). The number of subjects tested at 0, 50, 250, 1250, and 6250 AU/ml were respectively 20, 20, 20, 15, and 13 in the Placebo treatment condition; 20, 20, 20, 14, and 13 in the loratadine treatment condition; and 19, 19, 19, 15, and 13 in the CBP treatment condition.Back to article page